Huang SM - Search Results

1

The many sides of off-label prescribing.

Epstein RS, Huang SM. Epstein RS, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 May;91(5):755-8. doi: 10.1038/clpt.2012.37. Clin Pharmacol Ther. 2012. PMID: 22513307 No abstract available.

2

Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Huang SM, Temple R, Throckmorton DC, Lesko LJ. Huang SM, et al. Clin Pharmacol Ther. 2007 Feb;81(2):298-304. doi: 10.1038/sj.clpt.6100054. Clin Pharmacol Ther. 2007. PMID: 17259955 Review.

3

Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.

Leong R, Vieira ML, Zhao P, Mulugeta Y, Lee CS, Huang SM, Burckart GJ. Leong R, et al. Among authors: huang sm. Clin Pharmacol Ther. 2012 May;91(5):926-31. doi: 10.1038/clpt.2012.19. Clin Pharmacol Ther. 2012. PMID: 22472993

4

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies.

Yasuda SU, Zhang L, Huang SM. Yasuda SU, et al. Among authors: huang sm. Clin Pharmacol Ther. 2008 Sep;84(3):417-23. doi: 10.1038/clpt.2008.141. Epub 2008 Jul 9. Clin Pharmacol Ther. 2008. PMID: 18615002

5

Therapeutic protein-drug interactions and implications for drug development.

Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, Lesko LJ. Huang SM, et al. Clin Pharmacol Ther. 2010 Apr;87(4):497-503. doi: 10.1038/clpt.2009.308. Epub 2010 Mar 3. Clin Pharmacol Ther. 2010. PMID: 20200513

6

Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.

Khin NA, Yang P, Hung HM, Maung-U K, Chen YF, Meeker-O'Connell A, Okwesili P, Yasuda SU, Ball LK, Huang SM, O'Neill RT, Temple R. Khin NA, et al. Among authors: huang sm. Clin Pharmacol Ther. 2013 Aug;94(2):230-42. doi: 10.1038/clpt.2013.70. Epub 2013 Apr 3. Clin Pharmacol Ther. 2013. PMID: 23588316

7

Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice.

Huang SM, Temple R. Huang SM, et al. Clin Pharmacol Ther. 2008 Sep;84(3):287-94. doi: 10.1038/clpt.2008.144. Clin Pharmacol Ther. 2008. PMID: 18714314 Review. No abstract available.

8

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.

Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ. Huang SM, et al. Clin Pharmacol Ther. 2009 Nov;86(5):475-9. doi: 10.1038/clpt.2009.190. Clin Pharmacol Ther. 2009. PMID: 19844224

9

International Transporter Consortium commentary on clinically important transporter polymorphisms.

Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M; International Transporter Consortium. Giacomini KM, et al. Among authors: huang sm. Clin Pharmacol Ther. 2013 Jul;94(1):23-6. doi: 10.1038/clpt.2013.12. Clin Pharmacol Ther. 2013. PMID: 23778707

10

What is clinical utility and why should we care?

Lesko LJ, Zineh I, Huang SM. Lesko LJ, et al. Among authors: huang sm. Clin Pharmacol Ther. 2010 Dec;88(6):729-33. doi: 10.1038/clpt.2010.229. Clin Pharmacol Ther. 2010. PMID: 21081937 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,232 results

Search Page